Vanguard Group
CINC

Vanguard Group’s CinCor Pharma, Inc. Common Stock CINC Stock Holding History

Vanguard Group’s Portfolio CINC Stock Details CINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,064,718
Closed -$13.1M – 4620
2022
Q4 		$13.1M Sell
1,064,718
-107,112
-9% -$2.55M ﹤0.01% 2830
2022
Q3 		$38.5M Buy
1,171,830
+541,194
+86% +$15.3M ﹤0.01% 2308
2022
Q2 		$11.9M Buy
630,636
+11,352
+2% +$217K ﹤0.01% 2897
2022
Q1 		$10.9M Buy
+619,284
New +$12.7M ﹤0.01% 3105

Vanguard Group's CINC Position: Q1 2023 in Review

Vanguard Group sold out of CinCor Pharma, Inc. Common Stock (CINC) in Q1 2023, closing a stake of 1,064,718 shares — an estimated $13.1M sold.

Vanguard Group first reported a position in CINC in Q1 2022 and held it in 4 quarters. The position peaked at $38.5M in Q3 2022. 0 funds tracked by Wall St. Rank hold CINC as of Q1 2023.

  • Vanguard Group reported no remaining CinCor Pharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Vanguard Group sold 1,064,718 CinCor Pharma, Inc. Common Stock shares in Q1 2023, an estimated $13.1M.
  • Vanguard Group first reported a position in CinCor Pharma, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
  • Vanguard Group's CinCor Pharma, Inc. Common Stock position peaked at $38.5M in Q3 2022.
  • 0 funds tracked by Wall St. Rank held CinCor Pharma, Inc. Common Stock as of Q1 2023.

Based on Vanguard Group's 13F filing for Q1 2023, filed 15 May 2023.